Press Releases
May 28, 2019
Summary ToggleIntellia Therapeutics Names Laura Sepp-Lorenzino, Ph.D., Chief Scientific Officer
CAMBRIDGE, Mass. , May 28, 2019 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. , (NASDAQ:NTLA) has named Laura Sepp-Lorenzino , Ph.D., as its new executive vice president and chief scientific officer. Dr. Sepp-Lorenzino brings decades of leadership and research and development experience, and
May 2, 2019
Summary ToggleIntellia Therapeutics Announces First Quarter 2019 Financial Results and Company Update
Remains on track to submit investigational new drug application in 2020 for its first systemically delivered CRISPR/Cas9-based therapy, NTLA-2001, for treatment of transthyretin amyloidosis Expects to nominate first engineered cell therapy development candidate for treatment of acute myeloid
Apr 29, 2019
Summary ToggleIntellia Therapeutics Presents New In Vivo and Engineered Cell Therapy Data at the 22nd Annual Meeting of the American Society of Gene and Cell Therapy
Intellia scientists advance CRISPR-mediated targeted gene insertion in non-human primates Achieved normal circulating human Factor IX protein levels in non-human primates using targeted gene insertion High rate and specificity of acute myeloid leukemia cell killing progressed using genome-edited,
Apr 25, 2019
Summary ToggleIntellia Therapeutics to Hold Conference Call to Discuss First Quarter 2019 Earnings and Company Update
CAMBRIDGE, Mass. , April 25, 2019 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both in vivo and ex vivo , will present first quarter 2019 results and operational highlights in
Apr 15, 2019
Summary ToggleIntellia Therapeutics Announces Three Oral Presentations on In Vivo and Engineered Cell Therapy Data at the 22nd Annual Meeting of the American Society of Gene and Cell Therapy
CAMBRIDGE, Mass. , April 15, 2019 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), announced three oral presentations at the 22 nd Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT), taking place April 29-May 2, 2019 , in Washington, D.C.
Feb 27, 2019
Summary ToggleIntellia Therapeutics Announces Fourth Quarter and Full-Year 2018 Financial Results
Confirmed improved non-human primate liver editing and protein reduction of greater than 95 percent in transthyretin amyloidosis program; investigational new drug application on track for 2020 submission Engineered cell therapy platform will enable wholly owned development candidate for acute
Jan 24, 2019
Summary ToggleIntellia Therapeutics Names Fred Cohen, M.D., to Board of Directors
CAMBRIDGE, Mass. , Jan. 24, 2019 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both in vivo and ex vivo , has appointed Fred Cohen , M.D., D.Phil, F.A.C.P., to its board of
Dec 6, 2018
Summary ToggleIntellia Therapeutics and Novartis Expand Cell Therapy Collaboration to Pursue CRISPR/Cas9-based Genome Editing in Additional Stem Cell Population
– Intellia’s Right to Use Proprietary Lipid Nanoparticle Technology Extended to All Settings – Intellia Will Receive a One-time $10 Million Payment CAMBRIDGE, Mass. , Dec. 06, 2018 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing
Nov 8, 2018
Summary ToggleIntellia Therapeutics to Present at November Healthcare Investor Conferences
CAMBRIDGE, Mass. , Nov. 08, 2018 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both in vivo and ex vivo , will participate in the following upcoming healthcare conferences in
Oct 31, 2018
Summary ToggleIntellia Therapeutics Announces Third Quarter 2018 Financial Results and Corporate Developments
Enhanced in vivo CRISPR/Cas9 cargo components have led to substantially increased liver editing and protein reduction in non-human primates that could materially improve its transthyretin amyloidosis and other in vivo product profiles Integration of enhanced components into its lead transthyretin
